Cereno Scientific AB Class B
SSTO:CRNO_B3.17
SEK
+0.03
(+0.89%)
ISIN
SE0008241558
Return %
Stock
S&P 500
1Y
-57.01
14.20
3Y
-31.72
81.12
5Y
-27.26
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Sten Randahl Sörensen
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Mölndal Sweden
- IPO Date
- Jun 22, 2016
- Website
- cerenoscientific.com
- Similar Companies
- Business
- Cereno Scientific AB is a Sweden-based clinical-stage biotechnology company focused on the discovery, development, and commercialization of disease-modifying epigenetic and small-molecule therapeutics for severe and rare cardiovascular conditions, with a primary focus on pulmonary arterial hypertension, thrombosis prevention, and vascular fibrosis. Founded in 2012 and headquartered in Gothenburg, Sweden, the company operates within the biotechnology and pharmaceuticals sector, conducting clinical and translational research programs in collaboration with leading academic medical centers and specialized clinical research organizations across Europe and the United States. The company's core product development portfolio comprises three distinct therapeutic pipeline programs: CS1, a proprietary oral formulation of a histone deacetylase (HDAC) inhibitor acting as an epigenetic modulator designed to provide anti-thrombotic, anti-inflammatory, anti-fibrotic, and hemodynamic pressure-reducing therapeutic benefits for patients diagnosed with pulmonary arterial hypertension; CS014, a novel epigenetic HDAC inhibitor small molecule candidate developed to regulate platelet activation, vascular remodeling, and fibrinolysis without exacerbating bleeding risks in cardiovascular and thromboembolic indications; and CS585, a highly selective, stable synthetic prostacyclin (IP) receptor agonist licensed from the University of Michigan engineered for the prevention of thrombosis, vascular remodeling, and target-organ protection across cardiovascular and renal disease indications. In recent developments, Cereno Scientific has achieved several clinical, regulatory, and corporate milestones. The company completed its Phase II clinical study evaluating CS1 in patients with pulmonary arterial hypertension at clinical sites across the United States, utilizing Abbott's CardioMEMS HF System for continuous pulmonary arterial pressure monitoring to validate safety, tolerability, and hemodynamic efficacy, supported by Orphan Drug Designation (ODD) granted by the United States Food and Drug Administration (FDA) and the approval of an Expanded Access Program for continued patient treatment. In addition, the company advanced CS014 into Phase I first-in-human clinical development following preclinical safety and toxicology clearance, expanded its research collaboration with the University of Michigan to advance its preclinical pipeline, and completed strategic equity financing rounds on the Nasdaq First North Growth Market to fund clinical trial progression and operational expansion.